Lead how our earliest oncology assets progress from Phase 2 decisions through registration and launch, shaping evidence, access and diagnostic strategies that reflect local standards of care and payer expectations
Job Summary
Lead how our earliest oncology assets progress from Phase 2 decisions through registration and launch, shaping evidence, access and diagnostic strategies that reflect local standards of care and payer expectations.
Own Oncology-specific iLVA policy, criteria, and templates; define explicit no-go thresholds and fast-track pathways to enable timely, data-driven decisions.
Here your decisions directly shape how cutting-edge oncology medicines reach patients sooner, with real ownership to adapt for local standards of care and payer needs.
Matching Summary
Lead how our earliest oncology assets progress from Phase 2 decisions through registration and launch, shaping evidence, access and diagnostic strategies that reflect local standards of care and payer expectations.
Skills & Requirements
Must-have
Oncology asset strategy
Phase 2 through registration and launch
International market archetypes
Evidence generation for HTA
Cross-functional leadership
Companion Diagnostics strategy
Nice-to-have
Entrepreneurial thinking
Complex, fast-moving environments
Local ownership empowerment
Big data and real-world evidence
Key Requirements
Advanced scientific qualification (MD, PhD, or PharmD)
Deep Oncology expertise
Senior leadership integrating science and commercial strategy